Modulation of Steroid Immunosuppression by Alveolar Efferocytosis

This is an interventional basic science trial for Pulmonary Disease, Chronic Obstructive focused on measuring Apoptosis, Bronchoscopy, Human, Mice, inbred strains, Macrophages, Alveolar, MicroRNAs, Streptococcus pneumoniae, Fluticasone Read More

Inclusion Criteria:

• Inclusion Criteria for healthy subjects without COPD:
• Age 18-80 years, inclusive
• Males or females

• Never smoker (< 100 cigarettes in lifetime)

  • OR
• Current smoker (>10 pack-years) with normal spirometry
• Able to perform satisfactory spirometry
• Abe to give informed consent
• Able to complete questionnaires
• Inclusion Criteria for COPD subjects:
• Age 18-80 years, inclusive
• Males or females

• Current smoker

  • (>10 pack-years) & (≥1/2 pack/day)

    • OR

• Former smoker

  • (>10 pack-years) & (>6 months of non-smoking)
• Diagnosis of COPD by ATS/ERS1 criteria
• Able to perform satisfactory spirometry
• Able to give informed consent
• Able to complete questionnaires
• 1 ATS/ERS, American Thoracic Society/European Respiratory Society.

Exclusion Criteria:

• Exclusion Criteria for healthy subjects without COPD:
• Unstable cardiovascular disease, including uncontrolled hypertension, CHF, angina
• Significant renal (creatinine >2.5) or hepatic dysfunction (Childs B or C)
• Mental incompetence/active psychiatric illness
• Prednisone or other immunosuppressive medications
• Participation in another interventional experimental protocol within 6 weeks
• Pregnancy
• Use of antibiotics for any reason within 42 days
• Judged to be unsuitable for bronchoscopy by PI
• Resting SaO2<93%
• FEV1 < 70% predicted
• Respiratory infections within 42 days regardless of antibiotic use
• Diagnosed COPD or Asthma
• Use of inhaled corticosteroids
• Active pulmonary tuberculosis or other serious chronic respiratory infection
• Diffuse panbronchiolitis or Cystic fibrosis
• Clinically significant bronchiectasis
• History of thoracic radiation therapy for any cause
• Other inflammatory or fibrotic lung disease
• Exclusion Criteria for COPD subjects:
• Unstable cardiovascular disease, including uncontrolled hypertension, CHF, angina
• Significant renal (creatinine >2.5) or hepatic dysfunction (Childs B or C)
• Mental incompetence/active psychiatric illness
• Prednisone or other immunosuppressive medications
• Participation in another interventional experimental protocol within 6 weeks
• Pregnancy
• Use of antibiotics for any reason within 42 days
• Judged to be unsuitable for bronchoscopy by PI
• Resting daytime SaO2<90% while breathing room air
• FEV1 < 50% predicted
• Respiratory infections within 42 days regardless of antibiotic use
• Use of inhaled corticosteroids
• Active pulmonary tuberculosis or other serious chronic respiratory infection
• Diffuse panbronchiolitis or Cystic fibrosis
• Clinically significant bronchiectasis
• History of thoracic radiation therapy for any cause
• Other inflammatory or fibrotic lung disease